Helius Medical Technologies, Inc. Appoints Sherrie Perkins to its Board of Directors
March 17 2021 - 7:05AM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced the appointment of Sherrie Perkins,
effective March 15, 2021.
“Ms. Perkins’ career history includes over 20 years of
experience in the healthcare industry, including significant
experience advising neuromodulation companies on their commercial
and marketing activities,” said Blane Walter, Chairman of Helius’
Board of Directors. “We are pleased to expand our Board of
Directors with the appointment of Ms. Perkins and look forward to
leveraging her expertise and strategic insight as Helius prepares
its next phase of market development activities.”
“I am delighted to join the Board of Directors of Helius Medical
Technologies and appreciate the opportunity to help the company
advance its unique therapy in ways that provide meaningful benefit
to patients, physicians, and payers,” said Ms. Perkins.
Ms. Perkins currently serves as a member of the Venture
Mentoring Service at the University of Texas MD Anderson Cancer
Center, providing guidance and perspective on
commercialization-related topics that are important and relevant to
the progression of various ventures.
From 2017 to 2019, Ms. Perkins served as a consultant to
LivaNova, PLC (NASDAQ: LIVN), a global medical technology company
that designs, develops, manufactures and sells innovative
therapeutic solutions in the fields of neuromodulation and
cardiovascular disease. She previously spent 17 years at LivaNova
and its affiliates in several roles, including serving as Vice
President in the sleep apnea, new ventures space within the company
from 2015 to 2017, and as Vice President of Marketing and New
Business Development of Cyberonics, Inc. from 2011 to 2015.
Ms. Perkins received a B.S. in Medical Technology from
Mississippi State University and an M.A. in Management from Central
Michigan University.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on
neurological wellness. The Company’s purpose is to develop, license
and acquire unique and non-invasive platform technologies that
amplify the brain’s ability to heal itself. The Company’s first
commercial product is the Portable Neuromodulation Stimulator
(PoNSTM). For more information,
visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is authorized
for sale in Canada as a class II, non-implantable, medical device
intended as a short term treatment (14 weeks) of gait deficit due
to mild and moderate symptoms from multiple sclerosis (MS), and
chronic balance deficit due to mild-to-moderate traumatic brain
injury (mmTBI) and is to be used in conjunction with physical
therapy. The PoNS™ is an investigational medical device in the
United States, the European Union (“EU”), and Australia (“AUS”).
The device is currently under review for de novo classification and
clearance by the FDA. It is also under premarket review by the AUS
Therapeutic Goods Administration. PoNS™ is currently not
commercially available in the United States, the European Union or
Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.Jack Powell, Vice
Presidentinvestorrelations@heliusmedical.com
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on
historical facts and constitute forward-looking statements or
forward-looking information within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. All statements other than statements of historical fact
included in this news release are forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
often identified by terms such as “believe,” “continue,” “look
forward,” “will,” “committed to,” “goal,” “expect,” “remain,”
“hope” and similar expressions. Such forward-looking statements
include, among others, statements regarding the Company’s future
growth and operational progress, the next phase of the Company’s
market development activities, clinical and regulatory development
plans for the PoNS device, and potential regulatory clearance of
the PoNS device, including expected timing for the FDA to resume
its review of our request for de novo classification and clearance
and expected timing for receipt of the FDA’s decision on such
request.
These statements involve substantial known and unknown risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those expressed or implied by such
statements. Important factors that could cause actual results to
differ materially from the Company’s expectations include
uncertainties associated with the clinical development process and
FDA regulatory submission and approval process, including that the
Company’s request for de novo classification and clearance may be
declined by the FDA, that the FDA is not required to and may not
respond to the Company’s request in the timeframe indicated by its
de novo review goals or in the time the Company expects, whether
the Company’s response will be satisfactory to the FDA, whether the
FDA will require additional information, whether the Company will
be able to provide it in a timely manner and whether such
additional information will be satisfactory to the FDA,
uncertainties regarding the Company’s capital requirements to
achieve its business objectives, the impact of the COVID-19
pandemic, uncertainties associated with future clinical trials and
other development activities, and other risks detailed from time to
time in the filings made by the Company with securities regulators,
including the risks and uncertainties described in the “Risk
Factors” sections of the Company’s Annual Report on Form 10-K for
the year ended December 31, 2020 and its other filings with the
United States Securities and Exchange Commission and the Canadian
securities regulators, which can be obtained from either at
www.sec.gov or www.sedar.com.The reader is cautioned not to place
undue reliance on any forward-looking statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company assumes no
obligation to update any forward-looking statement or to update the
reasons why actual results could differ from such statements except
to the extent required by law.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this
news release.
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024